Effectiveness and safety of caplacizumab in acquired thrombotic thrombocytopenic purpura: health technology assessment and classification according to the methodology established in Colombia

Overview of attention for article published in International Journal of Technology Assessment in Health Care, July 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (84th percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

So far, Altmetric has seen 6 X posts from 4 X users, with an upper bound of 4,323 followers.

RT @jahirsotoepi: Compartimos la última publicación del grupo de @NeuroEconomix en conjunto con investigadores de Sanofi, en la revista má…

Compartimos la última publicación del grupo de @NeuroEconomix en conjunto con investigadores de Sanofi, en la revista más importante de HTA a nivel mundial @ijtahc. Open access https://t.co/sYu1lPULmF https://t.co/wOzL1OUeO6

RT @ijtahc: Just accepted! EFFECTIVENESS AND SAFETY OF CAPLACIZUMAB IN ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA: HTA AND CLASSIFICATIO…

RT @ijtahc: Just accepted! EFFECTIVENESS AND SAFETY OF CAPLACIZUMAB IN ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA: HTA AND CLASSIFICATIO…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.